Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study

EULAR ^® 2019

Systemic Sclerosis-Associated Interstitial Lung Disease

Distler et al. 2019. Nintedanib reduced decline in forced vital capacity across subgroups of patients with systemic sclerosis-associated interstitial lung disease: Data from the SENSCIS trial. Oral presentation presented at: EULAR 2019 Congress; 12–15 June 2019; Madrid, Spain.

Systemic Sclerosis

Hemodynamic response to treatment and outcome in pulmonary hypertension associated with interstitial lung disease versus pulmonary arterial hypertension in systemic sclerosis

Arthritis Rheumatol.

Chauvelot L, Gamondes D, Berthiller J, Nieves A, Renard S, Catella-Chatron J, Ahmad K, Bertoletti L, Camara B, Gomez E, Launay D, Montani D, Mornex JF, Prévot G, Sanchez O, Schott AM, Subtil F, Traclet J, Turquier S, Zeghmar S, Habib G, Reynaud-Gaubert M, Humbert M, Cottin V

doi: 10.1002/art.41512.

Systemic SclerosisFurther Publications Rheumatology

Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process

Semin Arthritis Rheum

Roofeh D, Barratt SL, Wells AU, Kawano-Dourado L, Tashkin D, Strand V, Seibold J, Proudman S, Brown KK, Dellaripa PF, Doyle T, Leonard T, Matteson EL, Oddis CV, Solomon JJ, Sparks JA, Vassallo R, Maxwell L, Beaton D, Christensen R, Townsend W, Khanna D

doi: 10.1016/j.semarthrit.2021.08.001

Systemic Sclerosis

Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis

Rheumatology (Oxford).

Hoa S, Bernatsky S, Steele RJ, Baron M, Hudson M

doi: 10.1093/rheumatology/kez407.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'

Ann Rheum Dis.

D'Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM, Choi HK, Sparks JA, Wallace ZS

doi: 10.1136/annrheumdis-2020-217888.

Further Publications Rheumatology

Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression

Respirology

Stock CJW, Hoyles RK, Daccord C, Kokosi M, Visca D, De Lauretis A, Alfieri V, Kouranos V, Margaritopoulos G, George PM, Molyneaux PL, Chua F, Maher TM, Abraham DJ, Ong V, Donovan J, Sestini P, Denton CP, Wells AU, Renzoni EA

doi: 10.1111/resp.13988

Further Publications Rheumatology

Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort study

Semin Arthritis Rheum

Vandecasteele E, Melsens K, Vanhaecke A, Blockmans D, Bonroy C, Carton C, Deschepper E, De Keyser F, Houssiau F, Piette Y, Vanthuyne M, Verbeke K, Westhovens R, Wuyts WA, De Langhe E, Brusselle G, Smith V

doi: 10.1016/j.semarthrit.2021.07.018

Systemic Sclerosis

STRATUS, a Phase II Study of Abituzumab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease

J Rheumatol

Khanna D, Tashkin DP, Wells AU, Seibold JR, Wax S, Vazquez-Mateo C, Fleuranceau-Morel P, Damian D, Denton CP

doi: 10.3899/jrheum.191365

RECOMMENDED

Systemic Sclerosis

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

★ 2 Recommended by Dr Martin Frey, Faculty Member

Ann Rheum Dis

Seibold JR, Maher TM, Highland KB, Assassi S, Azuma A, Hummers LK, Costabel U, von Wangenheim U, Kohlbrenner V, Gahlemann M, Alves M, Distler O, SENSCIS trial investigators.

doi: 10.1136/annrheumdis-2020-217331

Related content

Systemic Sclerosis-Associated Interstitial Lung Disease

Hemodynamic response to treatment and outcome in pulmonary hypertension associated with interstitial lung disease versus pulmonary arterial hypertension in systemic sclerosis

Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process

Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis

Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'

Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression

Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort study

STRATUS, a Phase II Study of Abituzumab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial